Bioventus Inc. BVS
11.00 USD +0.39 (+3.68%)
Nov 9, 2026, 12:07 PM EST
10.55 Day range 11.01
6.47 52-week range 15.89
- YTD
- +47.85%
- 1 year
- +47.65%
News
benzinga.com Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks were mixed as Nasdaq gained 1%; Pfizer beat Q3 estimates and raised 2026 guidance, while oil, gold and European shares fell.
benzinga.com Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18 Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and lowers the price target from $19 to $18.
benzinga.com Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed as Adeia plunges 23% after missing Q3 estimates and cutting FY26 guidance; Bioventus, Emergent and others also fall premarket.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
benzinga.com Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Aehr surged 15% after strong Q1 results and raised FY27 guidance; Mercer, HUB Cyber and Parabolic led gainers, while VCIG and Jaguar fell.
seekingalpha.com Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript Bioventus Inc. ( BVS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO &…
zacks.com Bioventus (BVS) Matches Q3 Earnings Estimates Bioventus (BVS) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.
marketbeat.com Bioventus Q3 Earnings Call Highlights Bioventus NASDAQ: BVS reported third-quarter revenue growth of 3% as strength in its Pain Treatments business, Ultrasonics operation and international markets was partly offset by softness in bone…
benzinga.com Bioventus Q3 2026 Earnings Call Transcript Bioventus (NASDAQ:BVS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Lowers FY2026 Sales Guidance from $600.000M-$610.000M to $590.000M-$595.000M vs $604.782M Est Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Lowers FY2026 sales outlook from $600.000 million-$610.000 million to $590.000…
benzinga.com Bioventus Q3 Adj. EPS $0.17 Beats $0.16 Estimate, Sales $142.442M Miss $149.461M Estimate Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent. This is a 13.33 percent increase over earnings of $0.15 per…
globenewswire.com Bioventus Reports Third Quarter Financial Results DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for…
benzinga.com Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19 Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
benzinga.com Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
benzinga.com Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy Major M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.
benzinga.com Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.76 percent increase over earnings of $0.21 per share from the same period…- benzinga.com Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000…
benzinga.com 5 Growth Stocks That Pass Peter Lynch's Favorite Test Wall Street loves to make stock selection sound like a combination of advanced calculus, artificial intelligence and whispered conversations with corporate executives in expensive restaurants. It…
benzinga.com Under the Radar: 3 Boring Small Caps That Could Return 10x Investors spend an enormous amount of time searching for the next stock that can rise 10 times in value. They study disruptive technologies, enormous addressable markets, charismatic founders, and…
benzinga.com Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans to acquire the company for $77 per share.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals…- benzinga.com Transcript: Bioventus Q1 2026 Earnings Conference Call
benzinga.com Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC Filing On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators, including the Company's Exogen® Ultrasound Bone Healing…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Bioventus Raises FY2026 Adj EPS Guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.747M Est Bioventus (NASDAQ:BVS) raises FY2026 Adj EPS guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000…
- benzinga.com Bioventus Q1 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $132.089M Beat $129.850M Estimate Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 87.5 percent increase over earnings of $0.08 per…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Barrington Research Maintains Outperform on Bioventus, Raises Price Target to $14 Barrington Research analyst Michael Petusky maintains Bioventus (NASDAQ:BVS) with a Outperform and raises the price target from $13 to $14.
- benzinga.com Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $16 Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $16.
benzinga.com Bioventus Q4 Earnings Assessment 
benzinga.com Bioventus Earnings Report: Q4 Overview 
benzinga.com Bioventus Sees FY2026 Adj EPS $0.73-$0.77 vs $0.77 Est; Sees Sales $600.000M-$610.000M vs $604.182M Est 2026 Financial Guidance Bioventus introduced its financial guidance for full-year 2026. The Company expects: Net sales of $600 million to $610 million. This reflects growth of approximately 6% to…- benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com Preview: Bioventus's Earnings 
benzinga.com This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com Barrington Research Initiates Coverage On Bioventus with Outperform Rating, Announces Price Target of $13 Barrington Research analyst Michael Petusky initiates coverage on Bioventus (NASDAQ:BVS) with a Outperform rating and announces Price Target of $13.
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Bioventus Affirms FY2025 Adj EPS Guidance of $0.64-$0.68 vs $0.71 Est; Affirms FY2025 Sales Guidance of $560.000M-$570.000M vs $565.200M Est 2025 Financial Guidance:Bioventus reiterated its 2025 Financial Guidance provided on May 6, 2025, including an estimated impact of tariffs, which is immaterial at this time. For the twelve months…
- benzinga.com Bioventus Q2 Adj. EPS $0.21, Inline, Sales $147.660M Beat $146.284M Estimate Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 31.25 percent increase over earnings of $0.16 per share from the same period…
benzinga.com Earnings Scheduled For August 6, 2025 - benzinga.com The FDA Grants 510(k) Clearances For Bioventus' Talismann And Stimtrial, Expanding The Company's Portfolio Of Peripheral Nerve Stimulation Solutions For Chronic Pain Management These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be…
- benzinga.com Cantor Fitzgerald Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $12 Cantor Fitzgerald analyst Ross Osborn initiates coverage on Bioventus (NASDAQ:BVS) with a Overweight rating and announces Price Target of $12.
- benzinga.com Bioventus Affirms FY2025 Adj EPS Guidance of $0.64-$0.68 vs $0.66 Est; Affirms FY2025 Sales Guidance of $560.00M-$570.00M vs $564.87M Est Bioventus (NASDAQ:BVS) affirms FY2025 Adj EPS guidance from $0.64-$0.68 to $0.64-$0.68 vs $0.66 analyst estimate. Affirms FY2025 sales outlook from $560.00 million-$570.00 million to $560.00…
- benzinga.com Bioventus Q1 Adj. EPS $0.08 Beats $0.02 Estimate, Sales $123.88M Beat $122.70M Estimate Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.02 by 300 percent. This is a 14.29 percent increase over earnings of $0.07 per…
- benzinga.com Earnings Scheduled For May 6, 2025
- benzinga.com Examining the Future: Bioventus's Earnings Outlook
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday - benzinga.com Earnings Scheduled For March 11, 2025
- benzinga.com Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings